Genital Herpes Treatment Market Growth, Size, Share, Trends, and Forecast 2032

Genital Herpes Treatment Industry Prospective:

The global genital herpes treatment market size was worth around USD 2,520 million in 2023 and is predicted to grow to around USD 5,120 million by 2032 with a compound annual growth rate (CAGR) of roughly 8.2% between 2024 and 2032.  

Request Free Sample     

Genital Herpes Treatment Market: Overview

The herpes simplex virus is the source of general herpes, a sexually transmitted illness or infection (STI). Painful blisters that affect the body's mucous membrane on the genitalia of both men and women can be used to diagnose genital herpes. When compared to males, women are more likely than men to get genital herpes. As a chronic illness, genital herpes has no known permanent cure as of yet. Nonetheless, there is medication available to reduce the disease's caused symptoms. Throughout the study period, rising STD awareness around the world is anticipated to continue to be an important driver in the genital herpes treatment market.

Key Insights

• As per the analysis shared by our research analyst, the global genital herpes treatment market is estimated to grow annually at a CAGR of around 8.2% over the forecast period (2024-2032).
• In terms of revenue, the global genital herpes treatment market size was valued at around USD 2,520 million in 2023 and is projected to reach USD 5,120 million, by 2032.
• The growing prevalence of genital herpes is expected to propel the market growth during the forecast period.
• Based on the drug type, the acyclovir segment is expected to dominate the market during the forecast period.
• Based on the route of administration, the oral segment is expected to grow at a significant rate over the forecast period.
• Based on the distribution channel, online pharmacies are expected to grow at the highest CAGR during the forecast period.
• Based on region, North America is expected to dominate the market during the forecast period.

Request Free Sample

Genital Herpes Treatment Market: Growth Drivers

Increased online purchasing of drugs drives the market growth

Due to price competition amongst already-existing online pharmacies, many businesses offer steep discounts to draw in new clients. Its customer base or market share should eventually grow as a result of this strategy. Online pharmacies can also draw clients by offering value-added services like free delivery. A variety of payment methods, including online banking, credit cards, debit cards, coupons, and cash on delivery (COD), are provided by businesses to their customers. Customers are more likely to want to buy drugs online because of these payment options' convenience. Companies also permit clients to make payments and purchases online without requiring them to create an account. All that businesses ask of their clients are their names, addresses, and phone numbers. Patients with genital herpes can conveniently obtain treatment medications from internet pharmacies. Online pharmacies offer a large selection of OTC medications as well as prescription medications. Online pharmacies offer a variety of brands of genital herpes medicines, such as GSK's Zovirax, Cipla's Valcivir, and Acivir 400 DT. As a result, the industry has room to expand as a result of the rise in online sales of medications for treating genital herpes.

Genital Herpes Treatment Market: Restraints

The social stigma associated with STDs hinders market growth

Social stigmas around sexually transmitted diseases are numerous. An inferior status that society bestows upon certain traits and circumstances is known as stigma. As a result of their sexual reluctance and feelings of shame, fear, embarrassment, rejection, and solitude, people with STDs frequently have low self-esteem. Post-diagnosis melancholy and self-hatred may be exacerbated by the discovery of STDs. Some persons may experience suicidal thoughts due to the social stigma associated with receiving a diagnosis of an STD. Depression can also result from keeping medical issues private from other people. Sexually transmitted diseases (STDs) can cause intimate relationship violence or lead to partner loss. There is no set manner in which STD stigma is applied. On the other hand, unintended stigma can cause emotional distress. Genital herpes is more socially stigmatized in low-income economies, which prevents people from talking about the illness and its treatment. Because STDs are stigmatized, many would rather not go to doctors' offices. These elements may impede the global market for genital herpes treatments from expanding.

Genital Herpes Treatment Market: Opportunities

Growing funding for research offers a lucrative opportunity for market growth

The increasing funding for research is expected to offer a lucrative opportunity for market growth during the forecast period. For instance, in October 2023, The National Institute of Health (NIH) granted $2.8 million to Rational Vaccines (RVx) to support ongoing research on the detection, management, and containment of the Herpes Simplex Virus (HSV). An estimated lifetime latent HSV infection affects over half of the human population. Although genital herpes is one of the most common Sexually Transmitted Infections (STIs) in the world, and many people identify with it, HSV can manifest itself in several ways, including ocular herpes and common cold sores. According to research, HSV can have serious, long-lasting repercussions on a person's health, including dementia and blindness.

Genital Herpes Treatment Market: Challenges

The high cost of treatment poses a major challenge to market expansion

Antiviral drugs for the treatment of genital herpes can be costly, especially for those without sufficient health insurance. Access to care may be hampered by the high expense of therapy, particularly for low-income groups in environments with limited resources. To guarantee equal access to genital herpes therapy, patient support programs, generic alternatives, and affordable treatment choices are required.

Genital Herpes Treatment Market: Segmentation

The global genital herpes treatment industry is segmented based on drug type, virus type, route of administration, distribution channel and region.

Based on the drug type, the global genital herpes treatment market is bifurcated into valacyclovir, acyclovir, famciclovir and others. The acyclovir segment is expected to dominate the market during the forecast period. Acyclovir is a member of the antiviral medication family, which is used to treat viral infections. These medications often only treat a single kind of viral illness or a subset of them. When someone has an HSV infection, acyclovir is used to stop genital herpes from developing. Moreover, it cures chickenpox around the mouth, shingles brought on by the varicella-zoster virus (VZV), and cold sores associated with herpes simplex. It functions by stopping the body's HSV from proliferating. Acyclovir comes in injectable, topical, and oral formulations that are sold in the market.

Based on the virus type, the global genital herpes treatment industry is segmented into HSV-1 and HSV-2.

Based on the route of administration, the global genital herpes treatment market is segmented into oral, topical and injection. The oral segment is expected to grow at a significant rate over the forecast period. The most popular mode of antiviral medication delivery is oral. Breaking a pill or capsule containing a sustained-release or slow-release medication may result in an earlier than anticipated release of the medication. Acyclovir (Zovirax), valacyclovir (Valtrex), and famciclovir (Famvir) are a few examples of genital herpes therapy tablets that may be prescribed in chronic suppressive doses to further lower the chance of transmission. Both the incidence of clinical recurrences and the rate of asymptomatic shedding are markedly reduced by these drugs.

Based on the distribution channel, the global genital herpes treatment industry is segmented into hospital pharmacies, retail pharmacies and online pharmacies. Online pharmacies are expected to grow at the highest CAGR during the forecast period. People no longer need to go to traditional brick-and-mortar pharmacies because online pharmacies offer a handy way for people to buy genital herpes drugs from the comfort of their homes. People who live in distant places or have limited mobility would particularly benefit from this ease.

Genital Herpes Treatment Market Report Scope

Regional Analysis

North America is expected to dominate the market during the forecast period

North America is expected to dominate the market over the forecast period. The largest share of the market can be ascribed to increased use of branded herpes medications, rising medical costs, more generic drug launches, and advantageous reimbursement practices. Through a variety of strategic efforts, major players are attempting to increase their market share. Furthermore, American players are increasing their profit margins by using their commercialization skills. As a result, the United States has a sizable portion of the market. Additionally, U.S.-based Rational Vaccines Inc. stated in August 2022 that it was starting an observational clinical trial with 200 patients for their vaccine RVx-001-PSS for recurrent HSV-2 infection. Thus, this is expected to drive the market growth in the region.

Genital Herpes Treatment Market: Competitive Analysis

The global Genital Herpes Treatment market is dominated by players like:

• Novartis AG
• GlaxoSmithKline plc.
• Sun Pharmaceutical Industries Ltd.
• Bausch Health Companies Inc.
• Teva Pharmaceutical Industries Ltd.
• Cipla Inc.
• Gilead Sciences Inc.
• Abbott
• Genocea Biosciences Inc.
• AiCuris Anti-infective Cures AG
• Moderna Inc.
• Reddy’s Laboratories Ltd.
• Pfizer Inc.

The Global Genital Herpes Treatment market is segmented as follows:

By Drug Type

• Valacyclovir
• Acyclovir
• Famciclovir
• Others

By Virus Type

• HSV-1
• HSV-2

By Route of Administration

• Oral
• Topical
• Injection

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa